TABLE OF CONTENTS

		Page
ACKNOWLEDGEMENT		III
ENGLISH ABSTRACT		IV
THAI ABSTRACT		V
LIST OF FIGURES		IX
ABBREVIATIONS		XI
CHAPTER I :	INTRODUCTION	1
	Transferrin receptor overexpression in cancer cells	2
	Ferric-Desferoxaminemesylate complex	3
	Application of ferrioxamine in MR imaging	4
	Objectives	6
CHAPTER II :	MATERIALS AND METHODS	7
	Chemicals	7
	Preparation of solutions	7
	Cell culture and cytotoxicity assay	8
	Measurements of T1- and T2-relaxation time of Proton	8
	MR Imaging of ferrioxamine distribution in Wistra rats	11
	Magnetic resonance angiography	11
	Statistical methods	12

CHAPTER III : RESULTS 13

Physicochemical properties of DFO in an aqueous solution 13

Potentiometric Titration 14

Complexation of DFO-ferric ion 14

Spectrophotometric titration of DFO by ferric ion 15

Spectrophotometric and potentiometric titration of Fe^{3+} - DFO complex 17

Measurement of T1 relaxation time and relaxivity of Fe(III)-DFO complex 19

Measurement of T2 relaxation time and relaxivity of Fe(III)-DFO complex 24

Bio-distribution in Wistra rats 28

CHAPTER IV : DICLUSSION AND CONCLUSION 33

CONCLUSION 37

CHAPTER V : REFERENCES 38

CURRICULUM VITAE 42

LIST OF FIGURES

Figure		page
1.1	chemical structure of desferoxaminemesylate and desferoxaminemesylate-ferric complex	3
2.1	Diagram of MRI sequence	10
3.1	Absorption spectra of DFO.	13
3.2	Variation of pH as a function of NaOH concentration	14
3.3	Absorption spectra of reaction products of DFO-Fe^{3+}.	15
3.4	Variation of absorbance at 427 nm as a function of the ratio of Fe^{3+} to DFO.	16
3.5	Variation of absorbance at 427 nm as a function of concentration of Fe^{3+}or DFO. The initial $[Fe^{3+}] = [DFO]$	17
3.6	Absorption spectra of DFO-Fe^{3+} in solution at indicated pH value	18
3.7	Variation of pH as a function of NaOH concentration. The initial $[DFO] = [Fe^{3+}] = 5x10^{-4}$ M	19
3.8	Variation of T1 relaxation time as a function of Fe(III)-DFO concentration	21
3.9	The relaxivity value of Fe(III)-DFO concentration.	22
3.10	T1W-images of Wistra rats pre- and post administrated of Fe(III)-DFO	23

Figure		page
3.12	T1 fat suppression image of Wistar rat	24
3.13	Variation of T1 signal intensity as a function of time.	25
3.14	Variation of T2 signal intensity measured using (a) 3.7% agarose gel, (b) RPMI 1640 and (c) distilled water (Fe(III)-DFO).	26
3.15	Variation of T2 relaxation time as a function of Fe(III)-DFO concentration	27
3.16	The relaxivity value of Fe(III)-DFO concentration.	28
3.17	T1W-images of Wistra rats pre- and post administrated of Fe(III)-DFO and of Gd-DTPA	29
3.18	T2W-images of Wistra rats pre- and post administrated of Fe(III)-DFO and of Gd-DTPA	30
3.19	T1 fat suppression coronal and cross section image of Wistar rat with anatomy label	31
3.20	Variation of T1 signal intensity as a function of time	32

ABBREVIATIONS

MRI	Magnetic resonance imaging
TfR	Transferin Recepter
Fe(III)-DFO	Ferric-Desferroxamine complex
GLC4	Small cells lung carcinoma
IC_{50}	The concentration of drug required to inhibit cell growth by 50%
T_1	Longitudinal relaxation time constant of spin decay
T_2	Transversal relaxation time constant of spin decay
ε	Molar extrinsion coefficient
MTT	Tetrazolium salt (3-(4,5-dimethyl-2-thiazolyl)-2,5- diphenyl -2H-tetrazolium bromide)
pKa	Proton dissociation constants
N_2	Gases nitrogen
Gd	Gadolinium
MW	Molecular weight
EDTA	Ethyline dihydrotetaacitate
FOV	Field of view
TSE	T1-weighted Spin Echo
TE	Time Echo
TR	Time Repletition
ROI	Region of interest
SI	Signal intensity
StdDev	Standard deviation
SNR	Signal-to-noise ratio